Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery
A Double-blind, Randomized, Parallel Study to Compare the Efficacy of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery in Patients With Severe Kidney Dysfunction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Ana Fernandez-Bustamante, M.D., Ph.D.
- Phone Number: 303-724-2935
- Email: ana.fernandez-bustamante@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University Of Colorado Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years or older
- Diagnosed with severe kidney dysfunction (defined by plasma creatinine clearance <30 mL/min)
- Planning on kidney transplantation surgery at the University of Colorado Hospital.
Exclusion Criteria:
- Patients unable to sign the informed consent
- Pregnant women
- Body Mass Index (BMI) > 40 kg/m2
- Pre-existing oxygen or ventilatory dependency (24h use of oxygen or other noninvasive or invasive ventilatory support)
- Patients with any pulmonary, neuromuscular or other disease that severely limits their respiratory functional status (e.g. unable to achieve 4 Metabolic Equivalent of Tasks, METs, such as climbing up 1 flight of stairs)
- Presence of any contraindication for any of the study-related medications or interventions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sugammadex
|
Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
|
|
Active Comparator: Neostigmine
|
Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07
mg/kg) at the end of the surgery before tracheal extubation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients With Hypoventilation in Post-anesthesia Care Unit (PACU)
Time Frame: Within up to 3 hours after the end of surgery
|
Presence of one or more episodes of hypoventilation in PACU, adjusted to qTOF and other confounders
|
Within up to 3 hours after the end of surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Kidney Graft Dysfunction
Time Frame: Within up to 3 postoperative days and at 14 +/- 3 days after surgery
|
Predefined kidney graft negative outcomes including: postoperative increasing ClCr, reduced daily urine output, need for dialysis postoperatively, and/or diagnosis of delayed graft function or kidney graft rejection.
|
Within up to 3 postoperative days and at 14 +/- 3 days after surgery
|
|
Rate of Adverse Events Related to NMBR Medications
Time Frame: Within up to 3 postoperative days
|
Adverse events related to NMBR medications, including hypersensitivity and any other adverse events
|
Within up to 3 postoperative days
|
|
Number of Patients With Presence of qTOF <0.9 in PACU
Time Frame: Within up to 3 hours after the end of surgery
|
Incidence of qTOF <0.9 in PACU
|
Within up to 3 hours after the end of surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ana Fernandez-Bustamante, M.D., Ph.D., University of Colorado School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Postoperative Complications
- Pathologic Processes
- Delayed Emergence from Anesthesia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Neurotransmitter Agents
- Cholinergic Agents
- Parasympathomimetics
- Cholinesterase Inhibitors
- Neostigmine
Other Study ID Numbers
Other Study ID Numbers
- 18-2707
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.